IgA Nephropathy Market Anticipated to Witness Massive Growth with a Tremendous CAGR of 40.83% in the 7MM for the Study Period of 2018-30 | DelveInsight

IgA Nephropathy market is expected to experience a growth boost mainly attributed to increased prevalence, anticipated launch of novel therapies, and also the key pharmaceuticals like Novartis, Calliditas Therapeutics, Chinook Therapeutics are setting foot in the IgA Nephropathy market domain

LAS VEGAS, Oct. 19, 2021 /PRNewswire/ -- DelveInsight's IgA Nephropathy Market Insights report proffers a detailed comprehension of IgA Nephropathy market size by treatment, epidemiology, emerging therapies, IgA Nephropathy market share of the individual therapies, current and forecasted IgA Nephropathy market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

Some of the salient features from the IgA Nephropathy Market Report: 

• The market size for IgA Nephropathy was USD 109.3 million in 2020 in the 7MM and is expected to grow at a CAGR of 40.83% for the study period 2018-2030.
• DelveInsight's analysts estimate that the IgA Nephropathy market is expected to show positive growth, mainly attributed to the increase in the prevalence of IgA Nephropathy and the anticipated launch of novel therapies during the forecast period.
• Key pharmaceutical companies in the IgA Nephropathy market such as Novartis, Calliditas Therapeutics, Chinook Therapeutics, Travere Therapeutics, Inc, Omeros, and others are involved in the development of IgA Nephropathy treatment therapies.
• The IgA Nephropathy pipeline therapies include Iptacopan, Nefecon, Atrasentan, Sparsentan, Narsoplimab, and others that are expected to launch in the study period 2018-30.
• According to DelveInsight analysis, among the studied geographies, the US accounted for 66.79% of the overall market size of IgA Nephropathy in 2020.
• Various studies by DelveInsight have assessed the prevalence of IgA Nephropathy in different worldwide regions and analyzed factors responsible for geographic differences. According to one such prominent study, IgAN is more frequent in Asian populations (45 cases per million population/year in Japan) than in Caucasians (31 cases per million population/year in France).

For further information on Market Impact by Therapies, Download IgA Nephropathy Market sample @ IgA Nephropathy Market Scenario

IgA Nephropathy: Overview

IgA Nephropathy is an autoimmune disease that attacks the kidneys. It affects blood filtration in the small blood vessels of the kidneys. IgA Nephropathy occurs when an abnormal protein damages the filtering unit (glomerulus) inside the kidneys.

Incidence of IgA Nephropathy occurs in men around two times more than females worldwide.

IgA Nephropathy Epidemiology Segmentation

DelveInsight's analysis indicates the total number of IgA Nephropathy prevalent cases in the 7MM countries was 377,829 in 2020. These cases are expected to rise by 2030, during the forecast period.

Also, as per DelveInsight's estimates, the US accounted for the highest population with IgA Nephropathy i.e. 127,360 cases among the 7MM countries in 2020.

The IgA Nephropathy Report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Total Prevalent IgA Nephropathy Cases 
• Gender-specific IgA Nephropathy Cases
• Age-specific Cases of IgA Nephropathy

Know how IgA Nephropathy Epidemiological Trends are going to look like in 2030 for the 7 MM by downloading @ IgA Nephropathy Epidemiological Insights

IgA Nephropathy Market Outlook

DelveInsight estimates the market size for IgA Nephropathy was found to be USD 109.3 million in 2020 in the 7MM. Also, the market size of IgA Nephropathy is anticipated to increase during the study period, 2018–2030.

Current IgA Nephropathy treatment options include corticosteroids, tonsillectomy, drugs like Aliskiren, Cyclosporine, and Mycophenolate Mofetil (immunosuppressive agent) as medications that can slow the progress of the disease and help manage symptoms such as high blood pressure, protein in the urine, and swelling. Although several new molecules are under investigation, there is still an absence of disease-specific treatment for IgA Nephropathy patients.

Since the entire IgA Nephropathy landscape was recently devoid of any approved pharmaceutical treatment option, any significant development in this direction is expected to create a tectonic impact on the existing IgAN market scenario. Some of the drugs in the pipeline include Nefecon, by Calliditas Therapeutics, a patented oral formulation of a potent and well-known active substance – budesonide – for targeted release. The formulation is designed to deliver the drug to the Peyer's patch region of the lower small intestine, where the disease originates, as per the predominant pathogenesis models. It is derived from the TARGIT technology, which allows the substance to pass through the stomach and intestine without being absorbed and released in a pulse-like fashion only when it reaches the lower small intestine.

Another major anticipated drug is Sparsentan from Travere Therapeutics Inc, it is a first-in-class, orally active, single-molecule that functions as a high-affinity dual-acting antagonist of both endothelin type A (ETA) and angiotensin II subtype 1 (AT1) receptors which are associated with kidney disease progression.

Discover more about therapy set to grab substantial IgA Nephropathy market share @ IgA Nephropathy Market Landscape

 IgA Nephropathy Pipeline Therapies and Key Companies

• Iptacopan: Novartis
• Nefecon: Calliditas Therapeutics
• Atrasentan: Chinook Therapeutics
• Sparsentan: Travere Therapeutics Inc.
• Narsoplimab: Omeros

To know about more pipeline therapies under different development phases visit @ IgA Nephropathy Pipeline Assessment, Patient Pool, and Emerging Therapies 

IgA Nephropathy Market: Drivers and Barriers

A robust pipeline of novel potential therapies as well as the discovery of new pathogenic mechanisms serves as major factors for IgA Nephropathy market growth in the coming years.  Increased prevalence, development of novel biomarkers, strategic partnerships among active players, and the anticipated launch of novel therapies during the forecast period also attribute to the expected surge in the IgA Nephropathy market. 

Now, the unreported and undiagnosed IgA Nephropathy cases, lack of in-depth understanding of the disease pathogenesis, challenges in drug development like low recruitment numbers are several  IgA Nephropathy market setbacks that can hold back the IgAN market. Heterogeneous clinical presentation and the variation in the prevalence of IgA Nephropathy are also considered some of the potential drawbacks.

There definitely are few factors acting as drawbacks for the IgA Nephropathy market, but DelveInsight estimates that the current understanding of IgAN has greatly improved in recent decades, leading to growing awareness, improved management, better outcomes, and consequently, will give rise to an increased IgA Nephropathy therapeutic market share.

Know which therapy is expected to score the touchdown first @ IgA Nephropathy Market Landscape and Forecast

Scope of the IgA Nephropathy Report

• Study Period: 2018-30
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Companies: Novartis, Calliditas Therapeutics, Chinook Therapeutics, Travere Therapeutics, Inc, Omeros
• Key  IgA Nephropathy Pipeline Therapies: Iptacopan, Nefecon, Atrasentan, Sparsentan, Narsoplimab
• Therapeutic Assessment:  IgA Nephropathy current marketed and emerging therapies
• Market Dynamics:  IgA Nephropathy market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs
• KOL's views
• Analyst's views
• Market Access and Reimbursement

Discover more about the future market share of IgA Nephropathy treatment therapies @ IgA Nephropathy Market Forecast

Table of Contents 

For further information on Market Impact by Therapies @ IgA Nephropathy Market Analysis

Get in touch with our Business executive @ IgA Nephropathy Market Landscape Analysis 

Related Reports

Graft-versus-host disease (GvHD) Market 

DelveInsight's "Graft-versus-host disease (GvHD) Market Insights Report" offers comprehensive details of pathophysiology and various diagnostic approaches, treatment algorithms. The report also offers profiling of pipeline therapeutics, ongoing clinical trials, key cross competition, and key pharmaceuticals involved like Medac, MaaT Pharma, ElsaLys Biotech (Mediolanum Farmaceutici Spa), Syndax Pharmaceutical, Kadmon Corporation, AstraZeneca, Biogen, Amgen, Pfizer, Bristol-Myers Squibb, CTI BioPharma, Novartis, GlaxoSmithKline, and several others.

IgA Nephropathy Epidemiology

DelveInsight's 'IgA Nephropathy (IgAN) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted IgA Nephropathy (IgAN) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Epstein-Barr Virus-associated Post-Transplant Lymphoproliferative Disease Market 

DelveInsight's "Epstein-Barr Virus-associated Post-Transplant Lymphoproliferative Disease - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Epstein-Barr Virus-associated Post-Transplant Lymphoproliferative Disease, treatment algorithms, profiling of pipeline therapeutics, ongoing clinical trials, key cross competition, and key pharmaceuticals involved.

Chronic Renal/Kidney Transplant Rejection Market 

DelveInsight's "Chronic Renal/Kidney Transplant Rejection - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Chronic Renal/Kidney Transplant Rejection, ongoing clinical trials, key cross competition, and key pharmaceuticals involved.

IgA Nephropathy Pipeline

DelveInsight's, "IgA Nephropathy – Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the IgA Nephropathy pipeline landscape. It covers the pipeline drug profiles and key companies involved such as Novartis AG, Reata Pharmaceuticals, Chinook Therapeutics, Aravive, Omeros Corporation, Vera Therapeutics, Apellis Pharmaceuticals, Inc,N and others

Lichen Planus Market

DelveInsight's "Lichen Planus - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Lichen Planus, historical and forecasted epidemiology, current treatment practices, emerging drugs, and unmet medical needs.

Guillain-Barre Syndrome Market

DelveInsight's "Guillain-Barre Syndrome (GBS) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Guillain-Barre Syndrome (GBS), historical and forecasted epidemiology, current treatment practices, emerging drugs, and unmet medical needs.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy Market

DelveInsight's "Chronic Inflammatory Demyelinating Polyradiculoneuropathy - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyradiculoneuropathy, historical and forecasted epidemiology as well as current treatment practices, emerging drugs,  treatment practice/algorithm, unmet medical needs.

Autoimmune Hepatitis Market

DelveInsight's "Autoimmune Hepatitis Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of Autoimmune Hepatitis, historical and forecasted epidemiology as well as current treatment practices, emerging drugs, and unmet medical needs.

Psoriatic Arthritis Market

DelveInsight's 'Psoriatic Arthritis (PsA)– Market Insights, Epidemiology, and Market Forecast—2030' report deliver an in-depth understanding of the historical and forecasted epidemiology profiling of pipeline therapeutics, and key pharmaceuticals involved like AbbVie, Amgen/Pfizer, Bristol-Myers Squibb, Janssen Biotech, Amgen, Eli Lilly and Company, Pfizer, UCB, Bristol-Myers Squibb, Sun Pharma Global FZE, and many others.

Browse Through Our Blog Posts

Graft vs Host Disease (GVHD): Treatment approaches and Trends

It is a well-known fact that where there is stem cell transplantation, there is Graft vs Host Disease (GVHD). The concept arose 2 decades ago and is not rare.

Autologous cell therapy market: A new paradigm for kidney diseases

The past few decades have seen significant advancements in the medical sector. Technological intervention is one of them.

Is Antibody-mediated Rejection a Roadblock to Organ Transplantation?

Over the last decades, organ transplantation has become the leading treatment option for patients with last-stage organ failure. 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg